PCM
CASC

Prelude Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Prelude Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-79,155
Closed -$293K – 1873
2017
Q4 		$293K Buy
+79,155
New +$324K 0.02% 531
2017
Q1 		– Sell
-100
Closed – – 1948
2016
Q4 		$0 Buy
+100
New +$646 ﹤0.01% 1943
2013
Q4 		– Sell
-1,515
Closed -$19K – 2086
2013
Q3 		$19K Buy
+1,515
New +$15.9K ﹤0.01% 1222

Prelude Capital Management's CASC Position: Q1 2018 in Review

Prelude Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 79,155 shares — an estimated $293K sold.

Prelude Capital Management first reported a position in CASC in Q3 2013 and held it in 3 quarters. The position peaked at $293K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Prelude Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Prelude Capital Management sold 79,155 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $293K.
  • Prelude Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 3 quarters.
  • Prelude Capital Management's Cascadian Therapeutics, Inc. position peaked at $293K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.